TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

PARTNER 3 update: TAVR still comparable to SAVR in low-risk patients after 7 years
PARTNER 3 trial has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025.
Medtronic launches FDA-cleared guidewire compatible with multiple TAVR systems
The guidewire was built specifically with Medtronic's own Evolut platform in mind. However, it is also compatible with all other commercially available TAVR systems.
ASE leading push to revise CPT code for interventional echocardiography
The pressure is on for ASE and other societies to create a new CPT code for the use of interventional echocardiography during structural heart procedures.
Medtronic announces new AI partnership focused on improving TAVR care
Participating TAVR programs will receive AI-powered recommendations courtesy of DASI Simulations.
SGLT2 inhibitors after TAVR may boost survival, limit bioprosthetic valve dysfunction
Prescribing these drugs to TAVR patients could improve certain clinical outcomes, according to a new study of nearly 27,000 adults.

Michael J. Mack, MD, discusses his team's seven-year update to the PARTNER 3 trial at TCT 2025 in San Francisco.

PARTNER 3 update: TAVR still comparable to SAVR in low-risk patients after 7 years

PARTNER 3 trial has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025.

Medtronic launches FDA-cleared guidewire compatible with multiple TAVR systems

The guidewire was built specifically with Medtronic's own Evolut platform in mind. However, it is also compatible with all other commercially available TAVR systems.

ASE leading push to revise CPT code for interventional echocardiography

The pressure is on for ASE and other societies to create a new CPT code for the use of interventional echocardiography during structural heart procedures.

heart data AI algorithm cardiologist doctor

Medtronic announces new AI partnership focused on improving TAVR care

Participating TAVR programs will receive AI-powered recommendations courtesy of DASI Simulations.

SGLT2 inhibitors after TAVR may boost survival, limit bioprosthetic valve dysfunction

Prescribing these drugs to TAVR patients could improve certain clinical outcomes, according to a new study of nearly 27,000 adults.

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

Performing PCI and TAVR together may improve in-hospital outcomes, long-term survival

When patients require PCI and TAVR, performing them at the same time is associated with both short- and long-term benefits.

Ismail El-Hamamsy, MD, PhD, director of aortic surgery for the Mount Sinai Health System, explains the long-term outcomes of the Ross procedure, where a diseased aortic valve is surgically replaced with the patient's own pulmonary valve.

Long-term data highlight Ross procedure's safety, effectiveness in younger patients

TAVR may get more attention, but the Ross procedure has also gained significant momentum in recent years. Ismail El-Hamamsy, MD, PhD, detailed his own team's success with the complex procedure.

DAPT during valve-in-valve TAVR may reduce stroke risk—more data still required

New research suggests there may be a cardiovascular benefit to considering dual antiplatelet therapy for valve-in-valve TAVR patients.